Study aim: The effectiveness of Corcomex in reducing the symptoms of Covid-19 Design: This clinical trial has a control group, double-blind, randomized, in phase 2 and on 100 people. The method of randomization was simple randomization. Settings and conduct: The study was conducted in the city of Sari. The study was double-blind, where the researcher, participants and data analysts were blind. Participants/Inclusion and exclusion criteria: Inclusion criteria: patients who had a ground glass opacity in the lung CT scan, Clinical symptoms of COVID19, having a history of contact with a corona patient, recent travel to high-risk areas, People who had a positive PCR result. Exclusion criteria: patients who were not able to take the medicine orally and the patient's lack of satisfaction in participating in the study. Intervention groups: Both groups will receive routine medications prescribed for outpatients. In addition to these treatments, one group will receive Curcomex capsules daily, and the control group will receive a placebo. Main outcome variables: Recovery time